All News
HEp-2 cell and ACR classification criteria:
Peter Lipsky @rhumnow #Rnl2022 https://t.co/6o6epkjqB4
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Avoid screening with ANA, PLEASE!!
Normal postive ANA
Peter Lipsky @rhumnow #Rnl2022 https://t.co/GEKmhQfpfm
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Remarkable heterogeneity in results of #ANA testing using different assays #PeterLipsky on “Almighty ANA” at #RNL2022 @RheumNow https://t.co/A0y3ugBBrz
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
ANA levels fluctuate & depend on the https://t.co/rjZhNvSzE1 should we use it as an entry criterion to diagnose lupus ? #RNL2022
Links:
madan madanpadmajan1 ( View Tweet)
ANA in otherwise healthy:
Anti-DFS70 antibodies (Dense Fine Speckled, 70kDa molecular weight) are a sub-group of anti-nuclear antibodies.
Peter Lipsky @rhumnow #Rnl2022 https://t.co/QH4qsdzZmu
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Q and A
Positive ANA post COVID infection and vaccination?
⬇️
1- Repeat test ( transient elevation).
2-Monitor clinical symptoms.
PS, COVID infection ▶️lupus anti coagulant and catastrophic APS like syndrome.
@RheumNow #Rnl2022
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
ANA variability among different platforms and essays.
Validated quantification test are needed!!
Peter Lipsky @rhumnow #rnl2022 https://t.co/pyJhBkJE8P
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Top Influencers of #RNL2022: @doctorRBC @hausmannMD @RheumNow @uptoTate @NoufAhmedAlham2 @Janetbirdope More 📊 https://t.co/5tIzMLfqrh
Symplur Hashtags healthhashtags ( View Tweet)
Dr. Kavanaugh reviews the process of guidelines/recommendations. It's a lot of work! #RNL2022 @RWCSmtg @RheumNow https://t.co/z48mVKweVq
Dr. Rachel Tate uptoTate ( View Tweet)
POD 3 on Psoriatic Arthritis Advances will begin at 2pm ET and Dr. Artie Kavanaugh will lead the first presentation of the pod titled PsA Guidelines: The Good, Bad & Ugly. #RNL2022 https://t.co/cx3XBSWbNr
Dr. John Cush RheumNow ( View Tweet)
Anifrolumab high incidence of herpes zoster #RNL2022
madan madanpadmajan1 ( View Tweet)
Dr. Narain: SLE flare risk w/ HCQ tapering/reducing dose vs maintaining.
Retinopathy risk:
💎doubles every 5 yrs of use
💎^ w/ ^ dosing per ABW
💎^ w/ IBW in dose-response manner
💎independent risk factors: cumulative HCQ use, duration of use, CKD, Asian decent #RNL2022 @RheumNow https://t.co/lgMNEmQEhl
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting potential upcoming SLE treatments
Data from China
Improvement of SRI-4 response rate compared to placebo
@RheumNow #RNL2022 https://t.co/VE5Tza7xt8
Robert B Chao, MD doctorRBC ( View Tweet)
Anifrolumab and lupus.
Don not forget Herpes zoster vaccination!!
Sonail Narain @RheumNow #Rnl2022 https://t.co/hNWaSHH27d
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#ClinicalPearl Maybe..2 approaches that may Rx #SLE. More data needed but restoring IL2 or use of Telitacept latter w BLyS & APRIL effects (B cell signalling) #RNL2022 @RheumNow https://t.co/qjHZH9Xg0k
Janet Pope Janetbirdope ( View Tweet)
Safety in pregnancy still not clear #RNL2022 https://t.co/xs8bxja2VX
madan madanpadmajan1 ( View Tweet)
Great talk by Sonail Narain at #Rnl2022 @RheumNow
Take home message!! https://t.co/rT8WNPRtvB
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Targeting the BLyS-APRIL signaling pathway in SLE
Sonail Narain @RheumNow #Rnl2022 https://t.co/g3MbO4swKy
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Role of Anti-CD-19 CAR-T therapy in treatment of refractory SLE?
Case reports only thus far
@RheumNow #RNL2022 https://t.co/0dIid7viZ5
Robert B Chao, MD doctorRBC ( View Tweet)
“Physician global impression on RA control changes DMARD prescription, while patient global changes DMARD adherence” —Dr. Michaud #RNL2022
Ara Dikranian RumorDoc ( View Tweet)